ESSA Pharma Inc
NASDAQ:EPIX
ESSA Pharma Inc
NASDAQ:EPIX
Price:
6.4 USD
Updated:
Apr 24, 2024
ESSA Pharma Inc
Cash from Operating Activities
Last
Value
3-Years CAGR
5-Years CAGR
|
ESSA Pharma Inc
Cash from Operating Activities Peer Comparison
Comparables:
ZYME
RPTX
FUSN
AUPH
SBFM
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ESSA Pharma Inc
NASDAQ:EPIX
|
Cash from Operating Activities
-$21.6m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Cash from Operating Activities
-$118.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Operating Activities
-$127.2m
|
CAGR 3-Years
-176%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash from Operating Activities
-$81.8m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Operating Activities
-$33.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-22%
|
|
|
Sunshine Biopharma Inc
OTC:SBFM
|
Cash from Operating Activities
-$8.8m
|
CAGR 3-Years
-137%
|
CAGR 5-Years
-77%
|
CAGR 10-Years
-32%
|
See Also
What is ESSA Pharma Inc's Cash from Operating Activities?
Cash from Operating Activities
-21.6m
USD
-21.6m
USD
Based on the financial report for Dec 31, 2023, ESSA Pharma Inc's Cash from Operating Activities amounts to -21.6m USD.
What is ESSA Pharma Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-16%
-16%
Over the last year, the Cash from Operating Activities growth was 23%. The average annual Cash from Operating Activities growth rates for ESSA Pharma Inc have been -7% over the past three years , -16% over the past five years .
You don't have any saved screeners yet
